SOURCE: Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

November 06, 2015 08:30 ET

Esperion Therapeutics to Present at November Healthcare Conferences

24th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2015

Stifel 2015 Healthcare Conference on Tuesday, November 17, 2015

ANN ARBOR, MI--(Marketwired - November 06, 2015) - Esperion Therapeutics, Inc. (NASDAQ: ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced Tim M. Mayleben, president and chief executive officer, will present at the 24th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Wednesday, November 11, 2015 at 11:30 a.m. Mountain Time/1:30 p.m. Eastern Time. Mary McGowan, MD, chief medical officer, will present at the Stifel 2015 Healthcare Conference in New York City on Tuesday, November 17, 2015 at 4:30 p.m. Eastern Time.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with hypercholesterolemia by developing therapies to lower LDL-C. Esperion scientists discovered ETC-1002 and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both ETC-1002 and a fixed dose combination of ETC-1002 and ezetimibe with a particular focus on patients with hypercholesterolemia who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia. ETC-1002 (bempedoic acid), the Company's lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. ETC-1002 inhibits cholesterol synthesis, decreases intracellular cholesterol, up-regulates LDL-receptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.

Contact Information